Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
axillary lymph node dissection
early-stage breast cancer
sentinel lymph node biopsy
survival
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
received:
01
02
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
1
9
2022
Statut:
epublish
Résumé
Currently, the standard method for staging and treatment of axillary lymph nodes for early-stage breast cancer is sentinel lymph node biopsy (SLNB), while axillary lymph node dissection (ALND) is used in cases with palpable axillary lymph nodes or positive SLNB cases. The aim of this review was to compare overall survival (OS), disease-free survival (DFS), and axillary recurrence in early-stage breast cancer patients underwent SLNB or SLNB and completion ALND. The databases of PubMed, Scopus, and Cochrane Library were searched using the key words of "breast cancer", "axillary lymph node dissection", and "sentinel lymph node dissection". In addition, other sources were searched for ongoing studies (i.e., clinicaltrials.gov). The clinical trials were evaluated based on the Jadad quality criteria, and cohort studies were evaluated according to the STROBE criteria. At the end of the search, the articles were screened independently by two reviewers to check their eligibility to be included in the study. Afterwards, the data were extracted independently by two researchers. After searching the databases, 169 papers were retrieved. However, after removing the duplicates and studying the titles and abstracts of these papers, only ten ones underwent further investigation. After reading full-text of each article, four studies were finalized. Following a manual search, 27 papers were entered into the study for the final evaluation, 11 of which were included in the meta-analysis based on the inclusion and exclusion criteria. The findings showed no significant differences in OS, DFS, and axillary recurrence in early-stage breast cancer patients underwent SLNB or SLNB and completion ALND. The findings did not confirm that ALND improved OS, DFS, and axillary recurrence in patients who were clinically node-negative and positive SLNB.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, the standard method for staging and treatment of axillary lymph nodes for early-stage breast cancer is sentinel lymph node biopsy (SLNB), while axillary lymph node dissection (ALND) is used in cases with palpable axillary lymph nodes or positive SLNB cases. The aim of this review was to compare overall survival (OS), disease-free survival (DFS), and axillary recurrence in early-stage breast cancer patients underwent SLNB or SLNB and completion ALND.
METHODS
METHODS
The databases of PubMed, Scopus, and Cochrane Library were searched using the key words of "breast cancer", "axillary lymph node dissection", and "sentinel lymph node dissection". In addition, other sources were searched for ongoing studies (i.e., clinicaltrials.gov). The clinical trials were evaluated based on the Jadad quality criteria, and cohort studies were evaluated according to the STROBE criteria. At the end of the search, the articles were screened independently by two reviewers to check their eligibility to be included in the study. Afterwards, the data were extracted independently by two researchers.
RESULTS
RESULTS
After searching the databases, 169 papers were retrieved. However, after removing the duplicates and studying the titles and abstracts of these papers, only ten ones underwent further investigation. After reading full-text of each article, four studies were finalized. Following a manual search, 27 papers were entered into the study for the final evaluation, 11 of which were included in the meta-analysis based on the inclusion and exclusion criteria. The findings showed no significant differences in OS, DFS, and axillary recurrence in early-stage breast cancer patients underwent SLNB or SLNB and completion ALND.
CONCLUSION
CONCLUSIONS
The findings did not confirm that ALND improved OS, DFS, and axillary recurrence in patients who were clinically node-negative and positive SLNB.
Identifiants
pubmed: 36037108
doi: 10.31557/APJCP.2022.23.8.2561
pmc: PMC9741898
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2561-2571Références
Ann Surg. 2016 Sep;264(3):413-20
pubmed: 27513155
In Vivo. 2019 Nov-Dec;33(6):1941-1947
pubmed: 31662523
BMC Surg. 2015 Jun 30;15:79
pubmed: 26123412
Natl Med J India. 2002 May-Jun;15(3):154-7
pubmed: 12186329
Ann Surg Oncol. 2013 Jan;20(1):120-7
pubmed: 22956062
Cancer Res Treat. 2019 Jul;51(3):1011-1021
pubmed: 30322228
Eur J Surg Oncol. 2007 Sep;33(7):832-7
pubmed: 17197151
Springerplus. 2016 Jan 27;5:85
pubmed: 26848425
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
Int J Surg. 2016 Oct;34:73-80
pubmed: 27562691
J Surg Oncol. 2006 Feb 1;93(2):109-19
pubmed: 16425290
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Ann Surg Oncol. 2014 Apr;21(4):1231-6
pubmed: 24318094
J Am Coll Surg. 2013 Jan;216(1):105-13
pubmed: 23122536
J Clin Oncol. 2006 Jan 20;24(3):337-44
pubmed: 16344321
Eur J Cancer. 2013 Mar;49(4):812-25
pubmed: 23084155
Ann Surg Oncol. 2020 Aug;27(8):2664-2676
pubmed: 32020394
Eur J Surg Oncol. 2009 Aug;35(8):805-13
pubmed: 19046846
Oncology. 2007;72(1-2):27-32
pubmed: 17998787
Ann Surg Oncol. 2014 Dec;21(13):4109-23
pubmed: 25081336
Breast Cancer. 2015 Nov;22(6):657-63
pubmed: 24756246
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Ann Surg Oncol. 2011 Jan;18(1):125-33
pubmed: 20652755
Eur J Surg Oncol. 2017 Apr;43(4):672-679
pubmed: 28139362
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Lancet Oncol. 2018 Oct;19(10):1385-1393
pubmed: 30196031
Int J Surg. 2016 Nov;35:58-63
pubmed: 27633450
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Breast Cancer Res Treat. 2011 Jan;125(2):301-13
pubmed: 20972825
Int J Breast Cancer. 2014;2014:513780
pubmed: 25383226
Mol Clin Oncol. 2020 Jul;13(1):48-53
pubmed: 32499914
Ann Surg Oncol. 2016 Aug;23(8):2494-500
pubmed: 26975739
Ann Surg Oncol. 2010 Oct;17 Suppl 3:343-51
pubmed: 20853057
Breast Cancer Res Treat. 2018 Jul;170(2):303-312
pubmed: 29526019
Eur J Surg Oncol. 2015 Aug;41(8):958-66
pubmed: 26054706
Cancer. 2012 Apr 15;118(8):1994-2003
pubmed: 21882186
Ann Surg Oncol. 2003 Dec;10(10):1140-51
pubmed: 14654469
J Clin Oncol. 2004 Jan 1;22(1):97-101
pubmed: 14701770
Ann Surg. 2008 Feb;247(2):207-13
pubmed: 18216523
Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):174-182
pubmed: 31085287
Breast. 2013 Jun;22(3):211-6
pubmed: 23478200
Breast Cancer Res Treat. 2013 May;139(1):125-34
pubmed: 23588950
Am J Surg. 2013 May;205(5):581-4; discussion 584
pubmed: 23592166
Am J Surg. 2002 Jan;183(1):23-7
pubmed: 11869698
Adv Radiat Oncol. 2019 Sep 27;5(2):163-170
pubmed: 32280815
J Clin Oncol. 2009 Jun 20;27(18):2946-53
pubmed: 19364968
BMC Cancer. 2017 Jul 1;17(1):459
pubmed: 28668073
Breast J. 2021 Feb;27(2):158-164
pubmed: 33368762
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Breast Cancer Res Treat. 2015 Sep;153(2):235-40
pubmed: 26283300